Brand-name market exclusivity for nebulizer therapy to treat asthma and COPD - Nature Biotechnology

  • 📰 NatureBiotech
  • ⏱ Reading Time:
  • 7 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 6%
  • Publisher: 63%

Indonesia Berita Berita

Indonesia Berita Terbaru,Indonesia Berita utama

Brand-name market exclusivity for nebulizer therapy to treat asthma and COPD

This work was funded by the Commonwealth Fund, as well as from a grant to W.B.F. A.S.K.’s work was also supported by Arnold Ventures. R.B.’s work is funded by an O’Brien Institute of Public Health catalyst grant for equitable pharmaceutical innovation and access to medicines. The funders had no role in the design and conduct of the study; collection, management, analysis or interpretation of the data; review or approval of the manuscript; or decision to submit the manuscript for publication.

Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada

 

Terima kasih atas komentar Anda. Komentar Anda akan dipublikasikan setelah ditinjau.

Brand name inhalers are very good at blocking competition, better even than nebulizers, study finds NBTintheNews via endpts

BrighamWomens harvardmed UCalgaryMed PORTAL_Research wbfeldman ReedBeall

Berita ini telah kami rangkum agar Anda dapat membacanya dengan cepat. Jika Anda tertarik dengan beritanya, Anda dapat membaca teks lengkapnya di sini. Baca lebih lajut:

 /  🏆 231. in İD

Indonesia Berita Terbaru, Indonesia Berita utama